Supply chain issues likely with Covid-19 vaccine Distribution

Supply chain issues likely with Covid-19 vaccine Distribution

Supply chain issues with vaccine: Very recently seen early data from a clinical trial with a coronavirus vaccine. And these data made me feel even more confident that we will be able to deliver a few hundred million doses of vaccine by the end of 2020.

That was one of President Trump’s new vaccine czars with his hopes for a COVID-19 vaccine. Wall Street’s placing its bets on one of those trials after McDermott therapeutics announced promising results this week from its phase one vaccine test. The pharmaceutical company, which is working with the federal agency, led by Dr. Anthony Fauci is receiving more than $400 million in government money to develop a coronavirus cure. Madonna is one of a dozen companies developing a vaccine, but it’s actually the first to make claims about his trial results.

The company says its data shows the eight patients developed antibodies for COVID-19 Sara overhaul is a health reporter, covering drug policy for Politico. And she joins me now. So, Sarah, I know you’ve covered this industry in-depth,

what degree of confidence?

Should we really look at Madonna’s apparent trial results isn’t really looking like we could potentially get a vaccine by the end of the year.

So we’re still going to learn more about these other patients.

It’s phase three, where a lot of drugs and vaccines fail, or we find out risks that we hadn’t seen before. So it’s really going to be that phase which they’re aiming to start in July, we’re going to get more of the answers. But to your second question about whether we could see a vaccine this year, we could have followed that goes right, but it’s a tricky game. And then we get to the next step, which is how to get it out to people.

How do they make that determination of who to get to it first?

And what does that process really look like?

Yes, that’s a very complicated process, generally speaking, and in outbreak situations, whether it be flu or Ebola in West Africa, they will go and administer it to healthcare workers first. And that makes a lot of sense because those are the frontline workers. And so that’s generally what happens first, after that, it becomes more complicated. It has to do with what kind of virus you’re dealing with, who is most at risk, and where the need really is. And so in the past, there have been pushes to prioritize the elderly, or children or pregnant women, or people who work in really high exposure areas.

In the past, we have let states make the decisions about who their priority lists are. But increasingly, there have been calls for the federal government to start laying this out themselves. One major concern, though, is that the way that the Trump administration has approached allotting resources during this pandemic has some people worried that outright health care ones.

You know, you mentioned the Trump administration’s approach to this and if there are calls for the federal government to intervene, overstates.

How did politics play out with the distribution of redeliver?

Exactly. So that’s the first one that we know of that has been effective against COVID-19. And there are not that many doses of it available. It’s quite a complicated drug to make. It felt it needed it, those doses in and so the federal government have plenty of data on what infections wait rates are, what the hotspots are, but they didn’t make it entirely clear why they were making the decisions that they were. And then it became this confusing sort of situation where some hospitals weren’t getting it or didn’t know whether they were eligible to get it, “Supply chain issues with vaccine”.

There were immediate blowback and criticism, and the Trump administration has since admitted that it probably didn’t use the best data to make those decisions. So people pointed out that which is a much more modest rollout than any vaccine would be because that was a few hundred thousand doses, this would be billions. And they worry that we’re not going to have a transparent process that your average person could look at and say, I understand why this is happening. I understand why this person is getting the vaccine before me.

How do they reach that scale?

Your report on concerns with the nation’s supply chain, but what challenges will the US face in trying to build that stockpile of a potential vaccine?

Right, they’re trying to address that right now. So something really unprecedented is happening. Normally, manufacturers, pharmaceutical manufacturers won’t actually start scaling up manufacturing, until they know for certain that what they have is going to be approved, and it’s going to be used. And so instead of doing that, and waiting, the federal government is pouring almost a billion dollars into trying to scale up for both Mandarina, which had those positive results this week, “Supply chain issues with vaccine”.

We Johnson and Johnson, which is another candidate that is far along as well, although not as far as Madonna. And the idea there is that if these do work, we immediately have doses available and there won’t be lag time, because we’re going to need hundreds of millions of doses just for the US. But we have to consider that everyone in the world is going to want this once it’s available. And there are immediate concerns, not just with the chemicals that you would need to make a vaccine, but things like glass vials and stoppers and syringes where there’s not really massive markets, to begin with.

the creation of a vaccine. Thank you for having me.

If you want to know more about “Supply chain issues with vaccine” You can Go Here

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *